Abstract
Objective: The paclitaxel-cisplatin-bevacizumab triplet is a standard therapy in metastatic, recurrent, and advanced cervical cancer. Before bevacizumab was introduced for cervical cancer, we used both the paclitaxel-cisplatin-ifosfamide triplet (TIP) or the paclitaxel-cisplatin doublet (TP). To date, the efficacy of the paclitaxel-cisplatin-bevacizumab triplet (TPA) has not been compared with that of TIP. In this study, we compared the efficacy of chemotherapy with that of TPA in patients with recurrent, persistent, or metastatic cervical cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
